[go: up one dir, main page]

MA27125A1 - Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose - Google Patents

Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose

Info

Publication number
MA27125A1
MA27125A1 MA26901A MA26901A MA27125A1 MA 27125 A1 MA27125 A1 MA 27125A1 MA 26901 A MA26901 A MA 26901A MA 26901 A MA26901 A MA 26901A MA 27125 A1 MA27125 A1 MA 27125A1
Authority
MA
Morocco
Prior art keywords
thienodibenzoazulene
compounds
factor inhibitors
tumor factor
necrosis tumor
Prior art date
Application number
MA26901A
Other languages
English (en)
Inventor
Mladen Mercep
Milan Mesic
Dijana Pesic
Zeljko Zupanovic
Boska Hracic
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of MA27125A1 publication Critical patent/MA27125A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

ABSTRACT La présente invention a trait aux compositions de dibenzoazulene représentées par la formule I ainsi que leurs préparations pharmaceutiques pour l'inhibition du facteur de nécrose de tumeurs alpha (TNF-a) et interleukine I (IL-I) chez les mammifères dans toutes les maladies et conditions oé ces médiateurs sont excessivement sécrétés. Les compositions de la présente invention démontrent également une action anlgétique et peuvent être utilisées pour soulager la douleur.
MA26901A 2000-05-17 2002-11-11 Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose MA27125A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HR20000310A HRP20000310A2 (en) 2000-05-17 2000-05-17 New dibenzoazulene compounds as tumor necrosis factor inhibitors

Publications (1)

Publication Number Publication Date
MA27125A1 true MA27125A1 (fr) 2005-01-03

Family

ID=10947110

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26901A MA27125A1 (fr) 2000-05-17 2002-11-11 Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose

Country Status (36)

Country Link
US (2) US6897211B2 (fr)
EP (1) EP1284977B1 (fr)
JP (1) JP2003533528A (fr)
KR (1) KR100823064B1 (fr)
CN (1) CN1194976C (fr)
AR (1) AR030562A1 (fr)
AT (1) ATE434619T1 (fr)
AU (2) AU2001256560B2 (fr)
BG (1) BG65967B1 (fr)
BR (1) BR0111202A (fr)
CA (1) CA2409090C (fr)
CR (1) CR6860A (fr)
CY (1) CY1109328T1 (fr)
CZ (1) CZ301770B6 (fr)
DE (1) DE60139070D1 (fr)
DK (1) DK1284977T3 (fr)
DZ (1) DZ3357A1 (fr)
EA (1) EA006069B1 (fr)
EE (1) EE200200636A (fr)
ES (1) ES2328335T3 (fr)
GE (1) GEP20043304B (fr)
HR (1) HRP20000310A2 (fr)
HU (1) HUP0302295A3 (fr)
IL (1) IL152809A0 (fr)
IS (1) IS6621A (fr)
MA (1) MA27125A1 (fr)
MX (1) MXPA02011269A (fr)
NO (1) NO20025510L (fr)
NZ (1) NZ522553A (fr)
PL (1) PL204849B1 (fr)
PT (1) PT1284977E (fr)
RS (1) RS50893B (fr)
SI (1) SI1284977T1 (fr)
SK (1) SK17702002A3 (fr)
WO (1) WO2001087890A1 (fr)
ZA (1) ZA200209180B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020303B8 (en) 2002-04-10 2009-03-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. Benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
HRP20020305A8 (en) * 2002-04-10 2009-03-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
HRP20020304B1 (en) 2002-04-10 2008-04-30 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the production thereof
HRP20020441A2 (en) * 2002-05-21 2003-12-31 Pliva D D 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
HRP20020440B1 (en) * 2002-05-21 2008-02-29 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 1-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
HRP20020452A2 (en) * 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
HRP20020451A2 (en) 2002-05-23 2003-12-31 Pliva D D 1-tia-3-aza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
HRP20030160A2 (en) * 2003-03-06 2005-04-30 Pliva-Istra�iva�ki institut d.o.o. 1-thiadibenzoazulene derivatives and biological action thereof
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
US20090018351A1 (en) * 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
HRP20030955A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030954A2 (en) * 2003-11-21 2005-08-31 Pliva D.D. USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20040104A2 (en) * 2004-01-30 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
CN101090908A (zh) 2004-10-27 2007-12-19 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 具有抗炎活性的共轭物
AU2005313325C1 (en) * 2004-12-07 2011-11-10 Janssen Pharmaceutica N.V. Substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives
EP1844053A2 (fr) * 2005-01-13 2007-10-17 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Conjugues de macrolides anti-inflamatoires
WO2007103540A2 (fr) 2006-03-08 2007-09-13 Pharmena North America Inc. Polytherapie presentant des inhibiteurs cox non selectifs en vue de prevenir des lesions gastriques liees a cox
US8389482B2 (en) 2007-01-30 2013-03-05 New York University Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species
WO2008096755A1 (fr) * 2007-02-07 2008-08-14 Nippon Suisan Kaisha, Ltd. Inhibiteur du récepteur vanilloïde (vr1) et son utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711489A (en) * 1971-03-31 1973-01-16 Pfizer Certain 8,9-dihydro(3,4,7,8)cycloocta(1,2-d)imidazoles
JPS53116385A (en) * 1977-03-19 1978-10-11 Hokuriku Pharmaceutical Pyrazin derivative and method for its production
US4198421A (en) * 1978-11-30 1980-04-15 E. I. Du Pont De Nemours And Company Antiinflammatory 2-substituted-dibenzo[2,3:6,7]oxepino[4,5-d]imidazoles
CA2232141C (fr) * 1996-04-12 2006-05-23 Janssen Pharmaceutica N.V. Derives tetrahydrofuranes tetracycliques substitues
GB9713368D0 (en) * 1997-06-25 1997-08-27 Weston Medical Ltd Flame control
EP0887339A1 (fr) * 1997-06-27 1998-12-30 Roche Diagnostics GmbH Dérivés de l'azulène et médicaments les contenant

Also Published As

Publication number Publication date
BR0111202A (pt) 2003-04-01
KR100823064B1 (ko) 2008-04-18
US20030153750A1 (en) 2003-08-14
YU84102A (sh) 2006-01-16
EP1284977A1 (fr) 2003-02-26
PL365054A1 (en) 2004-12-27
EA200201223A1 (ru) 2003-06-26
DZ3357A1 (fr) 2001-11-22
CZ301770B6 (cs) 2010-06-16
EP1284977B1 (fr) 2009-06-24
US20050171091A1 (en) 2005-08-04
PL204849B1 (pl) 2010-02-26
SK17702002A3 (sk) 2003-10-07
NO20025510L (no) 2003-01-14
CY1109328T1 (el) 2012-05-23
US6897211B2 (en) 2005-05-24
CN1194976C (zh) 2005-03-30
DK1284977T3 (da) 2009-09-14
IL152809A0 (en) 2003-06-24
CA2409090C (fr) 2010-06-29
EE200200636A (et) 2004-04-15
DE60139070D1 (de) 2009-08-06
HK1056719A1 (en) 2004-02-27
RS50893B (sr) 2010-08-31
CZ20024090A3 (cs) 2003-05-14
HUP0302295A2 (hu) 2003-10-28
CA2409090A1 (fr) 2001-11-22
EA006069B1 (ru) 2005-08-25
CN1437605A (zh) 2003-08-20
PT1284977E (pt) 2009-09-09
ES2328335T3 (es) 2009-11-12
CR6860A (es) 2008-06-02
SI1284977T1 (sl) 2009-10-31
GEP20043304B (en) 2004-02-10
NO20025510D0 (no) 2002-11-15
AR030562A1 (es) 2003-08-27
BG107399A (bg) 2003-09-30
HRP20000310A2 (en) 2002-02-28
MXPA02011269A (es) 2003-06-06
AU5656001A (en) 2001-11-26
BG65967B1 (bg) 2010-07-30
AU2001256560B2 (en) 2005-10-06
HUP0302295A3 (en) 2007-03-28
NZ522553A (en) 2005-04-29
WO2001087890A1 (fr) 2001-11-22
ZA200209180B (en) 2003-11-12
KR20030010625A (ko) 2003-02-05
JP2003533528A (ja) 2003-11-11
IS6621A (is) 2002-11-14
ATE434619T1 (de) 2009-07-15

Similar Documents

Publication Publication Date Title
MA27125A1 (fr) Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
EA200000718A1 (ru) Композиции целекоксиба
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
MA31890B1 (fr) Anticorps specifiques de la forme de protofibrille de proteine beta - amyloide
MA27132A1 (fr) Composes de n-(3-amino-2hydroxy-propyl)alkylamide substitues
LT2003002A (en) A soluble ctla4 molecule for use in the treatment rheumatic diseases
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
ATE456957T1 (de) Methode und zusammensetzung zur behandlung diabetischer neuropathie
UA90668C2 (ru) Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
DE69533194D1 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
WO2002067771A3 (fr) Recepteurs de chimiokine et maladies associees
ATE415965T1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
FI974444A0 (fi) N-hydroksiureayhdisteitä anti-inflammatorisina aineina
DE50109320D1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
MA29329B1 (fr) Derives d'amide en tant que ligands de canal ionique, compositions pharmaceutiques et methodes d'utilisation associees
MA54768B2 (fr) Gel antiseptique adapté pour les parties intimes
MA30267B1 (fr) Derives amides en tant que ligands de canal ionique et compositions pharmaceutiques et procedes d'utilisation de tels derives
RU2000121193A (ru) Средство для местного лечения язвенной болезни желудка и двенадцатиперстной кишки
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний
FR2832925B1 (fr) Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation